Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa inotuzumab

besponsa inotuzumab

Перейти к контенту

Главное меню:

besponsa inotuzumab
Besponsa | European Medicines Agency, About BESPONSA® | BESPONSA®, Inotuzumab ozogamicin - Wikipedia, inotuzumab ozogamicin (Besponsa) - scottishmedicines.org.uk, Besponsa (Inotuzumab Ozogamicin) | Lymphoma News Today, Besponsa (inotuzumab ozogamicin) | TheSocialMedwork, , , .
BESPONSA is associated with a risk of liver problems and increased risk of death after stem cell transplant. BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they:. The active substance in Besponsa, inotuzumab ozogamicin, is a monoclonal antibody (a type of protein) that has been linked to a small molecule, N-acetyl-gamma-calicheamicin dimethylhydrazide.. BESPONSA ® (inotuzumab ozogamicin) is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age..
History. In 2017 inotuzumab ozogamicin was approved by the European Commission and the FDA for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in 2017 under the trade name Besponsa (Pfizer/Wyeth).. Medicine details Medicine name: inotuzumab ozogamicin (Besponsa) SMC ID: 1328/18 Indication: As monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia.. Home » Besponsa (Inotuzumab Ozogamicin) Besponsa (inotuzumab ozogamicin, previously CMC-544) is an approved therapy developed by Pfizer to treat adults with B-cell precursor acute lymphoblastic leukemia (ALL) whose disease has relapsed or who did not respond to standard therapy.. Besponsa (inotuzumab ozogamicin) is is a medication used for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. . .
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню